Mustang Bio Inc MBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.70
- Day Range
- $0.64–0.69
- 52-Week Range
- $0.53–3.00
- Bid/Ask
- $0.64 / $0.70
- Shares Outstanding
- 7.58M
- Market Cap
- $5.03M
- Volume/Avg
- 54,027 / 133,537
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 4.67%
Company Profile
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.mustangbio.com
Valuation
|
Metric
|
MBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MBIO
|
|---|---|
Quick Ratio | 2.10 |
Current Ratio | 2.12 |
Interest Coverage | — |
Quick Ratio
MBIO
Profitability
|
Metric
|
MBIO
|
|---|---|
Return on Assets (Normalized) | −16.01% |
Return on Equity (Normalized) | −37.94% |
Return on Invested Capital (Normalized) | −45.41% |
Return on Assets
MBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>^RZ#PG | LOCK|vbcz | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|W>!skz | LOCK|?!%H | $70B | |||
| argenx SE ADR
ARGX
| LOCK|%bg&Zvn | LOCK|sT# | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|VTm<$P | LOCK|@P>f< | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%YMnC&^ | LOCK|j? | $36B | |||
| Moderna Inc
MRNA
| LOCK|NbJTn? | LOCK|^s | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CShTQ^> | LOCK|dmP$ | $25B | |||
| Incyte Corp
INCY
| LOCK|K#GMb@z | LOCK|&! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|NH^^!< | LOCK|bz | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|m#pNsG< | LOCK|<T? | $16B |
United States